Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Celgene Corporation. ZEPOSIA® (ozanimod) capsules: US prescribing information. 2020. http://www.accessdata.fda.gov/. Accessed 20 Apr 2020.
2. Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173(11):1778–92.
3. Tran JQ, Hartung JP, Peach RJ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol. 2017;57(8):988–96.
4. Celgene Corporation. Celgene reports first quarter 2018 operating and financial results [media release]. 4 May 2018. http://www.celgene.com.
5. Bristol-Myers Squibb. U.S. Food and Drug Administration approves Bristol Myers Squibbs ZEPOSIA® (ozanimod), a new oral treatment for relapsing forms of multiple sclerosis [media release]. 26 Mar 2020. http://www.bms.com/.
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献